Protocol SummaryBack To Search Instructions
Protocol No.1556GCCPrincipal InvestigatorHardy, Nancy
PhasePhase I
Age GroupAdult
TitleA Phase I Dose Escalation Open-Label Clinical Trial Evaluating the Safety and Efficacy of MAGE-A10c796T in Subjects with Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC).
DescriptionThe changed T cells used in this study will be your own T cells that have been genetically changed. The aim of your genetically changed T-cells is to attack and destroy the cancer cells in your lungs. Getting genetically changed T cells is an experimental treatment. There are no T cell treatments for cancer approved by the Federal Food and Drug Administration (FDA) or sold on the market at this time. For the purposes of this research, the FDA is allowing the use of these genetically changed T-cells.
TreatmentGenetically Modified T-cells responding to MAGE-A10 positive tumor cells
Key EligibilityPlease click on the live link below for eligibility criteria of the trial at www.clinicaltrials.gov.
Applicable Disease SitesLung
Therapies InvolvedChemotherapy (NOS)
Immunotherapy
Therapy (NOS)
Drugs InvolvedMAGE-A10^c796 T
MESNA
cyclophosphamide
fludarabine
StatusOpen
Treatment TypeTreatment
ClinicalTrials.gov http://www.clinicaltrials.gov/ct2/show/NCT02592577
ContactGreenebaum Comprehensive Cancer Center: Maha Khalil, PhD Phone:410-328-5009
Pager:
Email:mkhalil@umm.edu
Back to Protocol Listing